Cost-effectiveness of prehospital high-sensitivity troponin i testing versus standard emergency department care in patients with suspected acute coronary syndrome in France.
Health Economics Review · 2026-07-25 · Method & validation
Abstract
BACKGROUND: Prehospital point-of-care high-sensitivity cardiac troponin I (hs-cTnI) may support earlier triage of adults with suspected acute coronary syndrome (ACS). We assessed its short-term economic consequences compared with standard emergency department (ED)-based care in France. METHODS: We developed a decision-analytic, continuous-time semi-Markov model over a 24-hour horizon using individual patient data from the prospective, multicentre, double-blinded cohort study (VALIDATE) conducted across four French hospitals (July 2021-May 2024; n = 737). The reference analysis adopted a restricted prehospital-and-ED perspective covering measured medical and paramedical resources from first emergency medical service contact through ED disposition (states 1-3). A complementary database audit searched for patients recorded with less than 24 h of follow-up in an extended "prehospital, emergency department and hospital" setting. None were identified; inpatient, intensive care unit (ICU), coronary angiography, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) costs were therefore excluded from the reference-case totals. The initial hs-cTnI H0 sample was obtained before hospital arrival, whereas subsequent H1 or H3 samples, when required, were intended to be collected after arrival. Costs were reported in 2025 euros. Sampling uncertainty was assessed using 1,000 non-parametric bootstrap replications and scenario analyses examined clinically relevant subgroups (> 3 h since symptom onset; availability of a prehospital HEART score). RESULTS: Among 737 participants (mean age 65.4 years; 58.8% men), 77 (10.4%) had non-ST-segment elevation myocardial infarction. ED attendance was lower with hs-cTnI than with standard care (90.9% [95% CI 88.6-92.8] vs. 96.7% [95% CI 95.2-97.8]; absolute difference - 5.8% points [95% CI - 9.2 to - 2.4]; P < 0.001). Among ED attendees, mean ED length of stay was 1.63 h versus 2.76 h (P < 0.001). Mean prehospital-and-ED cost per patient was €185.24 with hs-cTnI and €268.55 with standard care, a saving of €83.31 ([95% CI 70.81-96.60]; P < 0.001). CONCLUSIONS: Within the restricted 24-hour prehospital-and-ED perspective supported by the available patient-level data, a strategy beginning with prehospital hs-cTnI testing was associated with fewer ED attendances, shorter ED stays and lower costs. Longer-term evaluations are planned because these findings do not establish system-wide for inpatient, wider organisational, patient and societal costs. TRIAL REGISTRATION: The VALIDATE study is registered with ClinicalTrials.gov (NCT04950244).
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Cost & cost-effectiveness · Point-of-care tests
Related articles
- Design and rationale of the HARTc 2.0 trial: A multicenter randomized controlled study on the impact of point-of-care high-sensitivity cardiac troponin-I testing in prehospital acute coronary syndrome triage on diagnosis and cost-effectiveness. (Am Heart J, 2025)
- Pre-hospital rule-out of non-ST-segment elevation acute coronary syndrome by a single troponin: final one-year outcomes of the ARTICA randomised trial. (Eur Heart J Qual Care Clin Outcomes, 2024)
- Prehospital risk assessment and direct transfer to a percutaneous coronary intervention centre in suspected acute coronary syndrome. (Heart, 2024)
- Rule-out of non-ST-segment elevation acute coronary syndrome by a single, pre-hospital troponin measurement: a randomized trial. (Eur Heart J, 2023)
- Chest Pain Management Using Prehospital Point-of-Care Troponin and Paramedic Risk Assessment. (JAMA Intern Med, 2023)
- Acute rule-out of non-ST-segment elevation acute coronary syndrome in the (pre)hospital setting by HEART score assessment and a single point-of-care troponin: rationale and design of the ARTICA randomised trial. (BMJ Open, 2020)